Literature DB >> 17626697

Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments.

Joseph V Vayalumkal1, Heather Whittingham, Otto Vanderkooi, Thomas E Stewart, Donald E Low, Michael Mulvey, Allison McGeer.   

Abstract

We report a case of fatal necrotizing pneumonia and sepsis caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in an otherwise well, 48-year-old Canadian man with type 2 diabetes mellitus who had travelled to Texas. Despite therapy that included intravenous antibiotics, intravenous immune globulin and other supportive measures, the patient succumbed to his illness. Recently, CA-MRSA pneumonia has been reported in several countries. The virulence of this organism may in part be related to its ability to produce toxins, such as Panton-Valentine leukocidin. As rates of CA-MRSA increase worldwide, physicians should be aware of the potential for MRSA to cause life-threatening infections in patients presenting to Canadian emergency departments (EDs). Necrotizing pneumonia caused by MRSA must be considered in the differential diagnosis of acute, severe respiratory illness. Early recognition of this syndrome in the ED may help physicians initiate appropriate antibiotic therapy in a timely manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626697     DOI: 10.1017/s1481803500015219

Source DB:  PubMed          Journal:  CJEM        ISSN: 1481-8035            Impact factor:   2.410


  9 in total

Review 1.  Severe necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by methicillin-resistant Staphylococcus aureus.

Authors:  Randall J Olsen; Kevin M Burns; Liang Chen; Barry N Kreiswirth; James M Musser
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

2.  Fulminant necrotising fasciitis by community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Lemuel Non; Aaron Kosmin
Journal:  BMJ Case Rep       Date:  2015-03-30

3.  Community-Associated Methicillin-Resistant Staphylococcus aureus in the Pediatric Population.

Authors:  Carrie W Nemerovski; Kristin C Klein
Journal:  J Pediatr Pharmacol Ther       Date:  2008-10

Review 4.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300.

Authors:  E L Brown; O Dumitrescu; D Thomas; C Badiou; E M Koers; P Choudhury; V Vazquez; J Etienne; G Lina; F Vandenesch; M G Bowden
Journal:  Clin Microbiol Infect       Date:  2008-12-22       Impact factor: 8.067

6.  High rates of Staphylococcus aureus USA400 infection, Northern Canada.

Authors:  George R Golding; Paul N Levett; Ryan R McDonald; James Irvine; Brian Quinn; Mandiangu Nsungu; Shirley Woods; Mohammad Khan; Marianna Ofner-Agostini; Michael R Mulvey
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

7.  Community acquired pneumonia with shock, severe hypoxemia and leucopenia: Is the etiology methicillin resistant Staphylococci?

Authors:  Garima Kapoor; Saurabh Saigal; Jai Prakash Sharma; Mohan Gurjar
Journal:  Saudi J Anaesth       Date:  2014-07

8.  Community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia without evidence of antecedent viral upper respiratory infection.

Authors:  Cristina Moran Toro; Jack Janvier; Kunyan Zhang; Kevin Fonseca; Dan Gregson; Deirdre Church; Kevin Laupland; Harvey Rabin; Sameer Elsayed; John Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-05       Impact factor: 2.471

9.  Macrophage-derived LTB4 promotes abscess formation and clearance of Staphylococcus aureus skin infection in mice.

Authors:  Stephanie L Brandt; Nathan Klopfenstein; Soujuan Wang; Seth Winfree; Brian P McCarthy; Paul R Territo; Lloyd Miller; C Henrique Serezani
Journal:  PLoS Pathog       Date:  2018-08-13       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.